Weleda remains stable in 2021
by Editor (comments: 0)
Weleda AG was able to achieve sales of 425 million Euros in 2021, thus remaining stable in difficult times. The operating result was below the previous year due to increased investments, while the consolidated annual result changed only insignificantly. The company presented its 2021 annual result to its 2022 Annual General Meeting.
The year 2021 was characterized by volatility and unpredictability due to the ongoing pandemic situation. Total sales of the Weleda Group increased slightly last year from 424 million euros to 425 million euros. The two business units, natural cosmetics and pharmaceuticals, developed differently.
While total sales of natural cosmetics increased by around 3 per cent compared to the previous year, pharmaceutical sales decreased by 10 per cent. In natural cosmetics, almost all regions contributed to growth. In the pharmaceuticals division, some markets recovered, while the French market continued to suffer from the discontinuation of reimbursement for homeopathic and anthroposophic medicines by health insurers.
The company continues to be debt-free
Operating profit in 2021 was 13 million Euros, less than the previous year (22 million Euros). This was mainly due to investments in the market, higher depreciation and amortization as a result of modernization and expansion of production facilities, and challenges in the pharmaceuticals division.
Due to lower foreign exchange losses and lower tax expenses, consolidated net income of 7 million Euros decreased only slightly compared to 2020 (8 million Euros). The profit generated enabled the equity ratio to be further increased to 54.1 per cent (previous year 53.8 per cent).
Net financial assets decreased by 5 million Euros in the financial year, mainly as a result of high investments, and amount to around 68 million Euros. The company continues to be debt-free.